Centre Francois Baclesse

6 trials 2 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

2 Completed trials

1 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (Other)

Phase III: 1 Phase II: 3 Phase IV: 1 Phase I (Other): 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Follicular thyroid cancer 1 Thyroid cancer 1 Papillary thyroid cancer 1 Non-small cell lung cancer recurrent 1 Glioblastoma 1

Top IMPs

ATEZOLIZUMAB 1 CABOZANTINIB 1 CARBOPLATIN 1 CISPLATIN 1 DOCETAXEL 1 FLUOROURACIL 1 FOLINIC ACID 1 NIVOLUMAB 1 OXALIPLATIN 1 SODIUM IODIDE (131I) 1 SPARTALIZUMAB 1

All trials

6 total

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending

2024-514144-85-02 Phase I (Other) 1 country
TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas… Pending

2024-516182-37-01 Phase II 1 country
Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting

2024-518991-30-00 Phase IV 1 country CABOZANTINIB; NIVOLUMAB
Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine ad… Recruiting

2024-514603-34-00 Phase III 1 country SODIUM IODIDE (131I)
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended

2024-516299-13-00 Phase II 1 country DOCETAXEL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; SPARTALIZUMAB
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended

2024-516201-23-00 Phase II 1 country ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN

Showing 1–6 of 6 trials

← All sponsors A–Z